EL7.AI
StocksMedium•16 November 2026•
4 min read

IDEAYA Plans Two Phase 3 Trials of IDE849 Before the End of 2026

Key Facts

1IDEAYA plans to start two registrational Phase 3 trials of IDE849 in small cell lung cancer and neuroendocrine cancer before the end of 2026.
2The neuroendocrine cancer analysis included 19 patients, with an overall response rate of 52.6% (10/19).
3Median progression-free survival was 7.0 months, and overall survival at nine months was 82.4%.
4The company expected preliminary data from its global Phase 1/2 trial by the end of 2026 or early 2027.

IDEAYA plans to start two registrational Phase 3 trials of IDE849 before the end of 2026, one for extensive-stage small cell lung cancer and the other for neuroendocrine cancer, according to a company update issued on November 3. The company said the plan follows successful Type C meetings with the U.S. Food and Drug Administration, but it did not publish details of the neuroendocrine cancer trial design in that update. It said details of the trial would be announced later, leaving the registrational path for this use undefined in information published as of that date. Results from another trial of the drug had shown antitumor activity in patients with neuroendocrine cancer, but those results do not mean the drug has received regulatory approval. The two planned trials remain part of a clinical development program targeting two different diseases, rather than two trials for neuroendocrine cancer alone.

In Phase 1 trial results announced by IDEAYA on October 23, the neuroendocrine cancer analysis included 19 patients and recorded an overall response rate of 52.6%, equivalent to 10 of 19 patients. Confirmed responses were 36.8%, or 7 of 19, according to the company statement. The analysis also recorded median progression-free survival of 7.0 months and an overall survival rate at nine months of 82.4%. The company presented these figures as preliminary results from a Phase 1 trial conducted by Hengrui in China, separate from the global trial sponsored by IDEAYA. The cohort size and type of analysis provide context for interpreting the reported rates, while these metrics remain early clinical results and are not a substitute for evaluation in registrational trials.

For the drug’s other indication, IDEAYA announced on August 31 that it had a successful Type C meeting with the FDA to determine the design of a registrational Phase 3 trial in patients with extensive-stage small cell lung cancer. The announced design targeted about 400 patients who had previously received tarlatamab, with randomization at a 1:1 ratio between IDE849 and investigator’s choice of treatment. The company identified overall response rate, as assessed by blinded independent central review, as a potential primary endpoint for accelerated approval. It designated median overall survival as the endpoint for full approval. The level of detail available for this path therefore differs from that for the neuroendocrine cancer trial, whose design the company had not provided in its November 3 update.

The treatment-comparison background for the lung cancer trial centers on tarlatamab, which the FDA granted traditional approval on November 19, 2025, for adults with extensive-stage small cell lung cancer whose disease progressed during or after platinum-based chemotherapy. The announced IDE849 design is limited to patients previously treated with tarlatamab, placing the study in the context of patients who have received prior treatment. In its August 31 update, IDEAYA said it was evaluating two IDE849 doses, 2.4 and 3.5 mg/kg, administered intravenously once every 3 weeks to select the recommended Phase 3 dose. That update did not specify which dose would ultimately be selected. Dose selection and details of the neuroendocrine cancer trial design remain elements of the development program that have not been fully disclosed in the available information.

For the next data releases, IDEAYA said on November 3 that preliminary data from its sponsored global Phase 1/2 trial in extensive-stage small cell lung cancer and neuroendocrine cancer were expected by the end of 2026 or early 2027. That timing follows publication in October of results from the neuroendocrine cancer cohort in the Phase 1 trial in China. The company also said it plans to start Phase 3 trials in both diseases before the end of 2026, without specifying a separate timeline for each trial in the published update. The company deferred details of the Phase 3 neuroendocrine cancer trial design to a later announcement. These milestones link the expected global data with the plan to move to registrational studies, while the timing of detailed announcements remains subject to what the company announces later.

Open on chart